Trial Profile
A phase III study of NOX-66 (Veyonda)
Status:
Planning
Phase of Trial:
Phase III
Latest Information Update: 06 Sep 2018
Price :
$35
*
At a glance
- Drugs Idronoxil (Primary)
- Indications Solid tumours
- Focus Registrational; Therapeutic Use
- Sponsors Noxopharm
- 06 Sep 2018 New trial record